Thursday, March 24, 2011
Rexahn Pharmaceuticals Inc., of Rockville, Md., enrolled 100 of a total 300 patients required for a Phase IIb trial of Serdaxin in major depressive disorder. Enrollment will be completed in the first half of 2011, with preliminary results expected in late 2011. The trial will measure changes from baseline on the Montgomery Asberg Depression Rating Scale.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.